Intelligence · Clinical Pipeline
Denali Therapeutics Pipeline
All ClinicalTrials.gov programs at Denali Therapeutics — phase, modality, and trial IDs.
- Programs
- 6
Quick answer
Denali Therapeutics has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
-, DNL593 Placebo, Sterile lyophilisate in single-dose glass vials, -, FAMOTIDINE
Denali Therapeutics
Frontotemporal Dementia (FTD)
1 trial -
A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants with Hunter Syndrome
Denali Therapeutics
Hunter Syndrome (Mucopolysaccharidosis Type II [MPS II])
1 trial -
BIIB122 225 mg
Denali Therapeutics
Parkinson Disease
1 trial -
BIIB122, Placebo to BIIB122
Denali Therapeutics
Parkinson’s disease
1 trial -
DNL126
Denali Therapeutics
Mucopolysaccharidosis Type IIIA
1 trial -
DNL593
Denali Therapeutics
Frontotemporal Dementia
1 trial
Frequently asked questions
How many pipeline programs does Denali Therapeutics have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs